MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing.
about
TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct MechanismsSpecific increase in potency via structure-based design of a TCR.Therapeutic Antibodies against Intracellular Tumor AntigensProinflammatory progranulin antibodies in inflammatory bowel diseases.Inactivation of protein-phosphatase 2A causing hyperphosphorylation of autoantigenic paraprotein targets in MGUS/MM is due to an exchange of its regulatory subunits.
P2860
MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
MHC-peptide-specific antibodie ...... tive intracellular processing.
@en
MHC-peptide-specific antibodie ...... tive intracellular processing.
@nl
type
label
MHC-peptide-specific antibodie ...... tive intracellular processing.
@en
MHC-peptide-specific antibodie ...... tive intracellular processing.
@nl
prefLabel
MHC-peptide-specific antibodie ...... tive intracellular processing.
@en
MHC-peptide-specific antibodie ...... tive intracellular processing.
@nl
P2093
P2860
P50
P356
P1476
MHC-peptide-specific antibodie ...... tive intracellular processing.
@en
P2093
Andreas Wadle
Carsten Zwick
Christine Sturm
Christoph Renner
Detlef Dieckmann
Frédéric Lévy
Gerhard Held
Gerold Schuler
Hennie R Hoogenboom
Markus Thiel
P2860
P304
P356
10.1002/EJI.200636545
P407
P577
2007-07-01T00:00:00Z